Abstract 285P
Background
Induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) and CCRT alone are both standard treatment regimens for managing locally advanced nasopharyngeal carcinoma (NPC). However, the results of comparisons between them in clinical trials vary. Therefore, we designed this meta-analysis to illustrate their advantages and disadvantages in patients with locally advanced NPC.
Methods
We thoroughly searched the PubMed, EMBASE, and Cochrane Library databases and then merged the effect indicators of hazard ratios (HRs) and risk ratios (RRs) using RevMan 5.1.
Results
Seven randomized controlled trials totaling 2,319 patients were included in our research. The synthesized results showed that IC plus CCRT improved overall survival (HR=0.74, 95% CI: 0.62-0.88, P< 0.001), progression-free survival (HR=0.66, 95% CI: 0.57-0.77, P< 0.001), distant metastasis-free survival (HR=0.65, 95% CI: 0.43-0.81, P<0.001) and locoregional recurrence-free survival (HR=0.68 95%, CI: 0.54-0.86, P=0.001) versus CCRT alone. It also increased the risk of anemia, thrombocytopenia, and neutropenia during CCRT. However, the incidence of leukopenia and mucositis was similar in IC and IC plus CCRT. Furthermore, the subgroup analysis showed better survival outcomes with IC plus CCRT than with CCRT alone in the triweekly cisplatin subgroup (all P<0.01), whereas IC plus CCRT could only improve progression-free survival and locoregional recurrence-free survival in the weekly cisplatin subgroup (HR= 0.71, P=0.02; and HR=0.66, P=0.03, respectively).
Conclusions
IC plus CCRT improved survival outcomes in patients with locally advanced NPC versus CCRT. For the weekly cisplatin regimen subgroup, it did not improve remote control or progression-free survival versus CCRT alone, warranting further clarification.
Clinical trial identification
The protocol of our study has been registered with PROSPERO, and the number is CRD42018087074.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
People's Government of Yunnan Province (no grant number is applicable).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
325P - Clinical characteristics and outcomes of cancer patients with COVID-19 infection: A retrospective study in a single center in the Philippines
Presenter: Frances Victoria Que
Session: e-Poster Display Session
326P - Management of diffuse large B cell lymphomas in the COVID-19 era
Presenter: David Ng
Session: e-Poster Display Session
327P - COVID-19 in patients with oncohematologic diseases in Kazakhstan
Presenter: Zaure Dushimova
Session: e-Poster Display Session
328P - Impact of COVID-19 pandemic on 30 days colorectal cancer patients mortality undergoing emergency operation
Presenter: Ida Bagus Budhi
Session: e-Poster Display Session
329P - Radiotherapy palliative and COVID-19: Experience of radiotherapy oncology department of Cancer Center Tlemcen, Algeria
Presenter: Asma Mous
Session: e-Poster Display Session
330P - COVID and cancer: Choosing between hammer and anvil
Presenter: Ullas Batra
Session: e-Poster Display Session
331P - The clock stopped with COVID-19 but continued ticking for cancer patients
Presenter: Sasi Shanmugam Senga
Session: e-Poster Display Session
336P - Efficacy of methylcobalamin administered intravenously for chemotherapy-induced peripheral neuropathy (CIPN): A prospective crossover study
Presenter: Jun Chen
Session: e-Poster Display Session
337P - A prospective study about the quality of life and chemotherapy-induced peripheral neuropathy
Presenter: Wala Ben Kridis
Session: e-Poster Display Session
338P - Vitamin E in the treatment of chemotherapy and radiation-induced mucositis: A meta-analysis of randomized controlled trials
Presenter: Michelle Joane Alcantara
Session: e-Poster Display Session